COVID-19 has profoundly impacted people's physical, emotional, and financial well-being. Vaccinations were developed to combat the physical health threats of the virus. However, studies suggest that the vaccinations themselves have contributed to anxiety, stress, and worry, leading to a lower rate of inoculation. Understanding and managing a pandemic requires a deep dive into how people are emotionally affected during such times and how they respond to public health initiatives like vaccines. To this end, a framework was proposed that analyzes behavioral responses from the general public's uninhibited discourses over one and a half years across five countries. The framework is built on the principle of knowledge differentiation, recognizing the mined emotional responses as basic knowledge nuggets (level zero of abstraction). Higher levels of abstraction are achieved by differentiating these basic knowledge nuggets. Simple, intuitive, and novel metrics for knowledge modelling was proposed, which consolidate and model the discovered knowledge, making it ready for practical use. From this framework, useful and insightful inferences have been drawn. The study analyzed 16 vaccines introduced in five countries over three different periods. Covaxin, initially available in Brazil and India, emerged as the most successful positive emotional influencer. AstraZeneca, first available in Brazil and the USA, was second, followed by Covishield in India and CoronaVac in Brazil. The framework also identified vaccines with the highest emotional intensities and top emotional ranks during the study periods. The insights from this proposed framework can guide government organizations in making informed decisions about the success of immunization drives and effectively curbing a pandemic. This approach highlights the importance of understanding emotional responses to enhance public health initiatives and pandemic management.